Kalshi Enters Biotech; Biogen Alzheimer's Drug in Question
SkimNews Take
By letting traders wager on trial readouts before results face peer-level scrutiny, biotech prediction markets turn opaque clinical data into a tradable signal that arrives faster than the scientific community can digest it.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Kalshi announced it is expanding into biotech, enabling bets on the outcomes of clinical trials and FDA drug reviews
- Jonathan Kimmelman, a McGill University bioethicist who has researched prediction in clinical trials, was brought on the podcast to discuss the ethical issues raised by the expansion
- Biogen presented mid-stage clinical trial data this week for its experimental tau-lowering Alzheimer's drug
- The drug reduced levels of the tau protein and slowed the rate of cognitive decline in patients
- The mixed data left experts and investors debating the drug's future amid raised questions about its viability
Why it matters: Kalshi's move puts prediction-market money on clinical trial and FDA outcomes — territory Kimmelman has specifically studied for ethical pitfalls. Biogen's mid-stage data gives the company its first encouraging Alzheimer's readout in years, with reduced tau and slowed cognitive decline, but the mixed expert and investor reaction leaves the drug's commercial path unresolved.
